Food allergy: A practice parameter update—2014 - 07/11/14
Doi : 10.1016/j.jaci.2014.05.013
Hugh A. Sampson, MD, Seema Aceves, MD, PhD, S. Allan Bock, MD, John James, MD, Stacie Jones, MD, David Lang, MD, Kari Nadeau, MD, PhD, Anna Nowak-Wegrzyn, MD, John Oppenheimer, MD, Tamara T. Perry, MD, Christopher Randolph, MD, Scott H. Sicherer, MD, Ronald A. Simon, MD, Brian P. Vickery, MD, Robert Wood, MD
Hugh A. Sampson, MD : Chief Editor, Christopher Randolph, MD : Chief Editor
David Bernstein, MD : Member of the Joint Task Force on Practice Parameters, Joann Blessing-Moore, MD : Member of the Joint Task Force on Practice Parameters, David Khan, MD : Member of the Joint Task Force on Practice Parameters, David Lang, MD : Member of the Joint Task Force on Practice Parameters, Richard Nicklas, MD : Member of the Joint Task Force on Practice Parameters, John Oppenheimer, MD : Member of the Joint Task Force on Practice Parameters, Jay Portnoy, MD : Member of the Joint Task Force on Practice Parameters, Christopher Randolph, MD : Member of the Joint Task Force on Practice Parameters, Diane Schuller, MD : Member of the Joint Task Force on Practice Parameters, Sheldon Spector, MD : Member of the Joint Task Force on Practice Parameters, Stephen A. Tilles, MD : Member of the Joint Task Force on Practice Parameters, Dana Wallace, MD : Member of the Joint Task Force on Practice Parameters
Hugh A. Sampson, MD : Chair, Practice Parameter Workgroup, Seema Aceves, MD, PhD : Practice Parameter Workgroup, S. Allan Bock, MD : Practice Parameter Workgroup, John James, MD : Practice Parameter Workgroup, Stacie Jones, MD : Practice Parameter Workgroup, David Lang, MD : Practice Parameter Workgroup, Kari Nadeau, MD, PhD : Practice Parameter Workgroup, Anna Nowak-Wegrzyn, MD : Practice Parameter Workgroup, John Oppenheimer, MD : Practice Parameter Workgroup, Tamara T. Perry, MD : Practice Parameter Workgroup, Christopher Randolph, MD : Practice Parameter Workgroup, Scott H. Sicherer, MD : Practice Parameter Workgroup, Ronald A. Simon, MD : Practice Parameter Workgroup, Brian P. Vickery, MD : Practice Parameter Workgroup, Robert Wood, MD : Practice Parameter Workgroup
Abstract |
This parameter was developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology (JCAAI). The AAAAI and the ACAAI have jointly accepted responsibility for establishing “Food Allergy: A practice parameter update—2014.” This is a complete and comprehensive document at the current time. The medical environment is a changing one, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, ACAAI, and JCAAI. These parameters are not designed for use by pharmaceutical companies in drug promotion.
Le texte complet de cet article est disponible en PDF.Key words : Food allergy, food allergen, cross-reactivity, adverse food reactions, IgE-mediated food allergy, eosinophilic esophagitis
Plan
| Disclosure of potential conflict of interest: H. A. Sampson has received research support from the National Institute of Allergy and Infectious Diseases (NIAID; AI44236 and AI66738), the National Institutes of Health (NIH; RR026134), and Food Allergy Research and Education (FARE); has received travel support as the chair of PhARF Award review committee; has consultant arrangements with Allertein Therapeutics, Regeneron, and the Danone Research Institute; and has received payment for lectures from Thermo Fisher Scientific, UCB, and Pfizer. S. Aceves is a member of the medical advisory panel for the American Partnership for Eosinophilic Disorders; has received research support from the National Institutes of Health (NIAID AI092135), the Department of Defense, and the American Academy of Allergy, Asthma & Immunology (AAAAI)/American Partnership for Eosinophilic Disorders; has a patent held by University of California–San Diego for OVB licensed to Meritage Pharma; and has received travel support from the NIH and the Falk Foundation. S. A. Bock is on the medical advisory board for FARE. S. Jones has received research support from the NIH (COFAR), the NIH/NIAID Immune Tolerance Network (A1-15416), and Food Allergy Research and Education. D. Lang is a speaker for Genentech/Novartis, GlaxoSmithKline, and Merck; has consultant arrangements with GlaxoSmithKline, Merck, Aerocrine; and has received research support from Genentech/Novartis and Merck. A. Nowak-Wegrzyn is a speaker for Thermo Fisher Scientific, is on the advisory board for Nutricia, is on the Data Safety Monitoring Board for Merck, and has received research support from Nestlé (grant 0955), Nutricia, and the NIH. J. Oppenheimer has received research support from AstraZeneca, GlaxoSmithKline, Merck, Boehringer Ingelheim, Novartis, and MedImmune; has provided legal consultation/expert witness testimony in malpractice defense cases; is chairman of the American Board of Allergy and Immunology; and has consultant arrangements with GlaxoSmithKline, Mylan, Novartis, and Sunovion. C. Randolph is a member of the Board of Regents for the American College of Allergy, Asthma & Immunology (ACAAI); has consultant arrangements with AstraZeneca and Genentech; has received payment for lectures from GlaxoSmithKline, AstraZeneca, Genentech, and TEVA; and has received travel support from TEVA. S. H. Sicherer has received research support from the NIAID, is a member of the American Board of Allergy and Immunology, has consultant arrangements with Novartis and FARE; and receives royalties from UpToDate. R. A. Simon has provided expert testimony for various law firms; has received payment for lectures from Merck, Novartis, and CSL-Behring; holds patents for the use of surfactants in chronic rhinosinusitis and asthma; has received royalties from Wiley Blackwell and UpToDate; and has stock options in URXmobile. B. P. Vickery has received research support from the NIH/NIAID (AI099083) and the Foundation of the ACAAI. R. Wood has consultant arrangements with the Asthma and Allergy Foundation of America, is employed by Johns Hopkins University, has received research support from the NIH, and receives royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest. |
|
| We thank Anne Munoz-Furlong for review and helpful comments to “Section IX: Management in special settings.” |
|
| Corresponding author: Susan L. Grupe, Joint Task Force on Practice Parameters, 50 N Brockway St, #304, Palatine, IL 60067. E-mail: grupes@jcaai.org. |
© 2014
Publié par Elsevier Masson SAS.
Vol 134 - N° 5
P. 1016 - novembre 2014 Retour au numéro
Article précédent
- Stress and asthma: Novel insights on genetic, epigenetic, and immunologic mechanisms
- Stacy L. Rosenberg, Gregory E. Miller, John M. Brehm, Juan C. Celedón
- The Editors' Choice
- Donald Y.M. Leung, Stanley J. Szefler, Associate Editors of the JACI
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?